C hronic kidney disease (CKD) is a major public health problem, estimated to affect 26 million Americans and 200 million individuals worldwide. 1, 2 Persons with CKD are at high risk of cardiovascular disease (CVD), progression to end-stage renal disease (ESRD), and allcause mortality. 3 Hypertension is a well-known risk factor for CVD; therefore, optimal blood pressure (BP) control is a major clinical and public health priority. 4, 5 Over the past decade, several studies and clinical practice guidelines [6] [7] [8] [9] [10] have addressed the optimal BP target in CKD populations, yet consensus remains elusive. Observational data have demonstrated U-shaped relationships between BP and mortality risk among those with CKD. 11, 12 Clinical trials testing different BP targets in CKD populations, including the Modification of Diet in Renal Disease (MDRD) 13 and the African American Study of Kidney Disease and Hypertension (AASK), 14 failed to demonstrate benefits of BP lowering for slowing down CKD progression and were underpowered to address CVD and mortality. The current Kidney Disease: Improving Global Outcomes (KDIGO) 7 BP guidelines recommend a BP goal less than 130/80 mm Hg for individuals with CKD and moderate to severe albuminuria and less than 140/90 mm Hg for those with CKD and albuminuria less than 30 mg/g. The Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) 15 and the 2013 European Society of Hypertension/European Society of Cardiology Task Force 16 affirmed the BP target of less than 140/90 mm Hg for individuals with CKD and made no distinction based on the albuminuria level. These guidelines were published before the Systolic Blood Pressure Intervention Trial (SPRINT) 17 was completed. SPRINT enrolled hypertensive individuals without diabetes and with high CVD risk and found a substantially lower CVD risk and lower all-cause mortality risk in participants treated to a systolic BP (SBP) target less than 120 mm Hg compared with less than 140 mm Hg, although they found a significant excess of acute kidney injury (AKI).
Patients with CKD (defined as an estimated glomerular filtration rate [eGFR] of 20-59 mL/min/1.73 m 2 ) accounted for approximately 30% of the SPRINT participants, and the results were similar (no statistically significant interactions) among those with CKD compared with their non-CKD counterparts. However, the trial was not specifically powered to define the risks and benefits of intensive BP control for those with CKD. The different definitions and differential reporting of AKI, CKD progression, and CVD events from previous randomized clinical trials (RCTs) represent a major challenge to comprehensively address these end points in a metaanalysis. In contrast, mortality is similarly defined across studies and is virtually always reported because it is an important safety signal. Mortality also provides a summary estimate of the net benefits and harms of the intervention. Therefore, our objective was to conduct a systematic review and meta-analysis of RCTs to investigate if more intensive compared with less intensive BP control is associated with reduced mortality risk in persons with CKD stages 3 to 5.
Methods

Electronic Searches
Ovid MEDLINE, Cochrane Library, EMBASE, PubMed, Science Citation Index, Google Scholar, and clinicaltrials.gov electronic database searches were completed from January 1, 1950, to June 1, 2016 , with the following keywords: randomized controlled trials, intensive blood pressure treatment, intensive blood pressure control, strict blood pressure treatment, strict blood pressure control, tight blood pressure treatment,o rtight blood pressure control. 18 The clinicaltrials.gov website was searched for randomized trials that were registered as completed but not yet published. The reference articles from each identified trial were reviewed to identify any additional relevant studies. No language restrictions were applied. The literature search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 19 statement recommendations (eTable 1 in the Supplement).
Selection of Studies
Study eligibility was individually determined independently by 2 of us (R.M. and H.A.N.). Eligible for inclusion were both open-label and double-blinded RCTs that had adult participants (≥18 years) with CKD stages 3 to 5, which was defined as an eGFR less than 60 mL/min/1.73 m 2 by either the MDRD or Chronic Kidney Disease Epidemiology Collaboration equations and had randomized participants to 2 defined BP targets (either active BP treatment vs placebo or no treatment, or more intensive vs less intensive BP control). In some instances, identified trials included persons with CKD, but the trials had not previously published mortality events within the CKD subset. In such cases, we contacted the study investigators and requested data on the number of patients with CKD enrolled in the trial, the number in each treatment arm, and the number of deaths that occurred during the active trial phase. Studies among dialysis patients were excluded.
reached. The quality and clinical generalizability of each study were assessed according to the methods based on allocation concealment, masking (of participants, investigators, and assessors), intent-to-treat analysis, percentage withdrawals, and whether withdrawals were adequately described.
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Outcome Measures
The primary outcome was all-cause mortality. The mortality data were obtained during the active treatment phase of each trial. The mortality events that occurred during extended follow-up after the active phase of each trial were not included.
Statistical Analysis
Mortality outcomes in each randomized BP group were pooled, and weighted odds ratios (ORs) comparing the lower BP arm (intensive BP) with individuals randomized to higher BP targets (less intensive or placebo) and their 95% CIs were calculated using both random-effects and fixed-effects models. The influence of individual trials on the pooled effect size was assessed, and a trial was considered to have an excessive influence if, after its exclusion, the point estimate of the remaining trials was outside the 95% CI of the overall risk estimate. Heterogeneity was assessed based on I 2 test (I 2 of 0%-25% indicates no or mild heterogeneity, 25%-50% indicates moderate heterogeneity, 50%-75% indicates large heterogeneity, and 75%-100% indicates extreme heterogeneity). 20 Subgroup analyses were performed stratified by type of study (drug vs placebo vs 2 defined BP target arms), study trial duration, inclusion of diabetic patients (yes or no), baseline SBP, level of achieved SBP during the trial phase, and SBP difference between the 2 randomized arms. Meta-regression analysis was performed to assess the association between SBP differences during the trial phase and mortality risk while adjusting for baseline SBP. Potential publication bias was assessed using funnel plots. Twosided P < .05 was considered statistically significant for all analyses, including tests for heterogeneity. All statistical analyses were performed using a software program (Comprehensive MetaAnalysis, version 2.2.064; Biostat Inc).
Results
Literature Search
The initial search of Ovid MEDLINE, Cochrane Library, EMBASE, PubMed, Science Citation Index, Google Scholar, and clinicaltrials.gov electronic databases between January 1, 1950, and June 1, 2016, provided 4416 citations. We reviewed abstracts and limited this search to a more detailed review of 407 abstracts of studies potentially eligible for inclusion as described in the Methods section. In subsequent review, 377 studies were excluded because they did not fulfill the inclusion criteria. The remaining 30 studies were reviewed in full text and identified for meta-analysis ( Figure 1 ). Data elements from 9 trials 13, 14, 17, [21] [22] [23] [24] [25] [26] [27] were extracted from the publications. One citation is a previous meta-analysis, 21 which was also used to abstract data. We contacted trial investigators for the remaining trials, and the authors of 9 studies 28-36 provided data on the number of participants with CKD and deaths during the trial phase for the 2 BP arms for the purpose of inclusion in this meta-analysis. We were unable to obtain mortality data in the CKD subset from the investigators for the remaining 12 trials. 37-48 Therefore, 18 RCTs involving 15 924 participants with CKD and complete data were included in the meta-analysis ( Figure 1 ). Figure 2 shows the main results of the meta-analysis. In the 18 included trials, there were 584 deaths among 7451 participants (7.8%) in the more intensive BP arm and 709 deaths among 8473 participants (8.4%) in the less intensive BP arm during the trial phase. Using the random-effects model, the OR for death among participants with CKD randomized to the more intensive BPlowering arm was 0.86 (95% CI, 0.76-0.97; P = .01) compared with the less intensive BP arm. The results were similar with the fixedeffects model. None of the individual trials had an excessive influence on the pooled effect size. There was no evidence of heterogeneity across studies (I 2 = 0%, P for heterogeneity = .77).
Study Characteristics
Funnel plot analysis revealed no evidence of publication bias based on visual inspection (Figure 3 ) or by performing Begg and Mazumdar rank correlation (P = .23) and Egger regression (P = .08) tests. Because we knew a priori that SPRINT had found that intensive BP control improved mortality and provided substantial statistical power to this meta-analysis, we specifically evaluated the remaining trials with the exclusion of SPRINT in a sensitivity analysis. The results were similar in this analysis (OR, 0.88; 95% CI, 0.78-0.99; P = .05).
Subgroup Analysis
The observed effect of those randomized to the more intensive BP arm on mortality was consistent irrespective of the following: type of treatment in the comparator arm (placebo or less intensive BP target), median follow-up duration (<3 vs In the trials that achieved a difference in SBP of at least 12 mm Hg, the OR of death in the more intensive vs less intensive arms was 0.76, trials with differences exceeding 6 but less than 12 mm Hg had an OR of 0.97, and those with differences of 6 mm Hg or less had an OR of 1.06; formal testing for heterogeneity resulted in a P value of .06. Meta-regression adjusting for baseline SBP level showed a similar pattern suggesting greater mortality benefit in trials with higher differences in achieved BP across treatment arms, although this finding did not reach statistical significance (slope of log OR per mm Hg difference in SBP, −0.0201; 95% CI, −0.0499 to 0.0097; P = .19) (eFigure in the Supplement).
Discussion
In this systematic review and meta-analysis of 18 RCTs among 15 924 participants with both hypertension and an eGFR less than 60 mL/min/1.73 m 2 randomized to more intensive vs less intensive BP lowering, those randomized to more intensive BP lowering had 14.0% lower risk of all-cause mortality. We observed a suggestion of a mortality benefit in studies that achieved the greatest difference in SBP between the 2 Approximately 30% of the SPRINT participants had CKD at baseline. 17 The primary end point of SPRINT was a composite CVD end point. While the P value for interaction for the primary CVD end point comparing those with and without CKD was not statistically significant (P = .36), the effect estimate was smaller and did not reach statistical significance in the CKD subgroup for the primary CVD end point (HR, 0.82; 95% CI, 0.63-1.07). Moreover, intensive BP control resulted in higher risk of a 30% decline in the eGFR among those without CKD, as well as more rapid loss of the eGFR, and greater AKI events in the SPRINT participants both with and without CKD at baseline. In SPRINT, those with CKD randomized to the intensive BP-lowering arm had a statistically significant reduction in all-cause mortality (HR, 0.72; 95% CI, 0.52-0.98; P = .04). However, the total number of deaths in the SPRINT CKD subgroup was low (70 deaths among 1330 individuals in the intensive BP group vs 95 deaths among 1336 individuals in the standard treatment group), and the trial excluded persons with diabetes, proteinuria greater than 1000 mg/g, and prior stroke. It was unknown whether the results generalize to other subsets and whether the mortality benefit observed in the SPRINT participants with CKD was reproducible. The present metaanalysis extends these findings and provides additional assurance in a larger study sample and across different settings. Overall, we found little heterogeneity across studies and a similar mortality benefit in persons treated with more intensive BP lowering. The highest mortality benefit was observed in studies that achieved the greatest difference in SBP during the trial, a result that did not reach statistical significance (P = .06 for heterogeneity).These data will need to be reevaluated when additional trials evaluating intensive BP control among those with CKD are completed. Nonetheless, this preliminary finding supports our overall conclusion that more intensive BP control may be beneficial for individuals with CKD. The size of the mortality reduction in patients with CKD (14%) is similar to the percentages (9% and 11%) calculated in recent meta-analyses 52, 53 of all BP-lowering trials, and this result suggests that the benefits of BP lowering on all-cause mortality do not differ substantially in the presence or absence of CKD.
The findings of this meta-analysis may have implications to both clinical practice and public health policy. Relative to public policy, the KDIGO Blood Pressure Work Group 54 announced that they have convened a panel of experts to review evidence and potentially modify their guideline recommendations regarding appropriate BP targets in patients with CKD. The present meta-analysis may provide useful data for the upcoming guideline review. Our results may also offer additional information for patients and health care professionals and may be useful to guide shared decision making about the relative risks and benefits of BP lowering among those with CKD.
Strengths and Limitations
This study has several strengths. First, multiple high-quality, methodologically rigorous randomized trials had not previously reported differences in death rates across treatment arms in persons with prevalent CKD. Among the 18 trials included in this meta-analysis, investigators from 9 trials reevaluated their data within the CKD subset and provided data specifically to support this study. Therefore, our metaanalysis provides a substantial new evidence base about the risks and benefits of intensive BP lowering in populations with CKD. Second, we assessed mortality as a hard clinical 
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Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease outcome, which has obvious clinical importance, is similarly ascertained across studies, and is thus largely free of bias. Third, we restricted our analysis to outcomes that were assessed during the trial phase of each study only and excluded events that occurred during long-term follow-up. While there is important information obtained in such follow-up, 55,56 BP control often approached similar levels across treatment arms after the trial phase.
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Our study also has important limitations. First, despite considerable efforts to contact investigators, we were not able to obtain data on mortality in persons with CKD in several prior clinical trials. Therefore, these trials were excluded by necessity. Among the 18 studies with almost 16 000 participants with CKD, we found no evidence of heterogeneity. This observation provides confidence, although not certainty, that the results would likely have been similar with the inclusion of additional studies. Second, we lacked data by severity of CKD and thus could not evaluate the effect of more intensive BP lowering on mortality stratified by CKD severity. Most individuals in the included trials had CKD stage 3, and we acknowledge that the risks and benefits of more intensive BP lowering may differ in persons with more advanced CKD. Third, baseline BP and the intensity of BP reduction in the randomized treatment arms differed across the individual trials. As such, we are not able to provide an estimate of an optimal BP target in patients with CKD. We recognize that CVD events, CKD progression, AKI, and ESRD are important factors that may be in the causal pathway between more intensive BP lowering and mortality and were not able to assess these end points.
Conclusions
Among trial participants with hypertension and an eGFR less than 60 mL/min/1.73 m 2 , randomization to more intensive BP lowering was associated with lower risk of all-cause mortality. This finding was consistent across trials, with no evidence of heterogeneity. A nonsignificant suggestion of greater mortality benefit was observed in trials that achieved the greatest difference in SBP across arms. Although additional studies and intensive monitoring for safety are warranted, these data support that the net benefits may outweigh the net harms of more intensive BP lowering in persons with CKD. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
